

NHSBT Finance Report

December 2022

Contents	Page
Executive Summary	2
Financial Performance Headlines	3-4
NHSBT – Summary I&E Statement	5
Divisional I&E statements	6-9
Cash & Debtors	10
Contribution Statement	11

Executive Summary

December Results: overall financial position ahead of plan primarily driven by Blood and Group transformation

- Year to date revenue reporting £5.6m ahead of budget, predominately reflecting transformation underspends.
- Capital spend up to December is £4.5m.
- Cash at the end of December was £70m.

Blood and Group: Q3 forecast remains confident that we can continue to operate within our financial envelope for 2022/23

- The Q3 forecast reported increase costs against budget of £2.6m, reflecting the strengthened Blood Supply capacity, unfunded pay inflation and increased marketing initiatives, partially offset by a lower transformation plan.
- This is an improved view, versus the position that was reported quarter 2, primarily driven by further reductions in the 2022/23 transformation plan.
- Subsequently, the latest cash forecast and shows a small improvement above the working capital threshold (£12m vs £10m), creating a small reserve going into 2023/24 to meet any under delivery on the budget envelope.
- Looking forward to 2023/24, the latest pricing envelope will be presented to the NCG in February, with latest plans resulting in a transformation plan of £12m

ODT: latest forecast now implies a small operating surplus.

- Q3 forecast reports a small underlying surplus position (£0.6m surplus versus a budget deficit of £1.8m)
- This is predominately driven by reduced activity expenditure (forecast based on 1,430 donors versus a plan of 1,646)
- Discussions ongoing with DHSC to agree funding envelope for 2023/24, in order to manage the expected growing deficit for the Service c£5m.
- Agreement received from DHSC to draw down funding to match DCD hearts expenditure for 2022/23. However, there is a risk that this will not be funded from 2023/24 onwards.

TES: continues to report a full year income shortfall of £1.7m driven by lower than plan cornea activity

- This shortfall is currently being funded by Blood cash reserves.
- A income reset is planned for 2023/24, dependant on pathway for Corneas and increased pricing (elasticity) to achieve contribution – this is a potential risk against the Blood cash reserve.

Clinical Services: All business units forecasting to exceed budget contribution this year, with exception of CBC

- CBC reporting an adverse position against plan due to slippages in high value contracts (full year outturn £1.3m adverse).
- It is expected that the CBC 2023/24 business model will incorporate mitigation, to avoid cross-subsidies from other Clinical Services business units

Plasma: fully funded for 2022/23

- For 2022/23, the Plasma plan is fully funded by a combination of cash reserves and Plasma for Diagnostics income.
- Discussions are on going with NHS England to finalise an SLA which will fully fund collection costs from circa mid 2023/24 onwards.


Capital Plan

- Latest plan circa £12m vs £21m plan. DHSC to be advised on final drawdown

2022/23 NHSBT Financial Performance Headlines - December 2022


Year to date surplus of £6.7m for NHSBT overall, £5.6m ahead of plan

Blood and Group Net Income & Expenditure (excl. Change Programme and Plasma)




Blood and Group in line with budget, Blood Supply overspends being largely offset by favourable variances in Group Services- detail on page 5 & 6.

Clinical Services Net Income & Expenditure (Business unit contribution)




£0.8m behind plan – operating units are £0.3m ahead of plan. This is more than offset by transformation spend of (-£1.2m).

Organ Donation & Transplantation Net Funding & Expenditure




ODT are reporting £1.8m favourable variance against plan. This is driven by lower activity related expenditure - detail on page 8

Blood and Group Change Programme Full Year Outturn




Full year forecast £10.8m, versus the £17m plan. The difference is mostly due to re-categorisation of Blood Tech Modernisation expenditure to capital and reprofiled Colindale spend.

NHSBT Cash Flow 2022/23



Forecast cash balance at the end of March 2023 is £47m

NHSBT I&E Full Year Outturn



Forecast outturn of the end of March 2023 is £8.1m. The improvement versus Q2 forecast driven by reduced transformation spend combined with additional DCD Hearts funding in ODT.

2022/23 NHSBT Financial Performance Headlines – December 2022

Year to Date	£6.7m surplus vs £1.1m budget surplus	Blood/Group	+£5.3m	Lower transformation spend.	
		Plasma	-£0.2m	The adverse position reflects an increase in funding available to c/fwd. into 2023/24, arising from lower than expected overhead costs charged (and with the off-setting benefit) through the ABC contribution statement.	
		Clinical Services	-£0.9m	BAU – business units are reporting £0.4m ahead of plan. Transformation - £1.2m expenditure year to date (budget profiled into M12)	
		OTDT	+ £1.4m	ODT (+£2.1m) – lower activity related expenditure TES (-£0.7m) – Cornea income shortfall.	
Full Year Forecast (at Q3)	£8.1m deficit forecast vs £8.1m deficit budget	Blood/Group	-£2.6m	Pressures in Blood Supply, partially offset by Change Programme underspends – detail on 5 & 6.	
		Plasma	-£0.3m	ABC allocation £0.3m lower than budget estimates (carry forward as cash to 2023/24).	
		Clinical Services	+£2.3m	Lower costs due to unfilled vacancies and reduced transformation spend.	
		OTDT	+£0.7m	ODT (+£2.4m) – Lower activity related expenditure. TES (-£1.7m) – Cornea activity lower than plan.	
Cash and Debtors	Cash balance £70m	Debtor Days		19 days – ahead of target (22 days)	
		90+ day overdues		£0.6m (within £0.5m - £1.0m target range).	
		Cash		Cash balance forecast at the end of March 2023 is £47m. Notionally; Blood £13.7m, CS £7.9m, ODT £11.3m, Plasma £14.6m	


Arrow direction indicates the direction of performance vs previous month. Colour demonstrates performance against standards and expectations

NHSBT Summary I&E statement - December 2022

Dec			WTE		Year to Date			Full Year			
Budget	Actual	Variance	Budget	Actual	Budget	Actual	Variance	Prev. Yr Actual	Budget	Q3 Forecast	Variance
Blood and Group											
1,036	933	(102)			9,321	8,400	(921)	11,461	12,428	11,200	(1,228)
25,590	25,468	(122)			230,156	229,744	(413)	292,274	306,827	306,427	(400)
280	275	(5)			2,621	3,016	395	3,864	3,512	4,017	505
500	600	100			4,578	4,828	250	5,272	6,091	6,379	288
27,406	27,276	(129)			246,676	245,987	(688)	312,872	328,857	328,023	(834)
(18)	(950)	(933)		0	776	1,124	348	(2,305)	0	1,080	1,080
(13,442)	(14,420)	(978)		2,462	(123,640)	(129,556)	(5,915)	(163,543)	(163,952)	(172,927)	(8,975)
(14,970)	(15,693)	(723)		1,222	(136,767)	(133,406)	3,361	(168,895)	(182,936)	(183,078)	(142)
(1,481)	(131)	1,350		0	(12,576)	(4,361)	8,215	(12,213)	(16,999)	(10,753)	6,246
(29,911)	(31,195)	(1,283)		3,684	(272,207)	(266,198)	6,009	(346,956)	(363,886)	(365,677)	(1,791)
(2,506)	(3,918)	(1,413)		3,684	(25,531)	(20,210)	5,321	(34,085)	(35,029)	(37,654)	(2,626)
Plasma for Medicine											
1,176	1,068	(108)			10,580	10,885	305	29,483	14,107	8,646	(5,461)
682	759	77			5,455	5,645	191	1	7,500	9,840	2,340
1,857	1,827	(30)			16,034	16,530	496	29,484	21,607	18,486	(3,121)
0	0	0		0	0	0	0	1,076	0		
(884)	(878)	6		122	(7,941)	(8,661)	(721)	(29,484)	(16,493)	(8,673)	2,303
(884)	(878)	6		122	(7,941)	(8,661)	(721)	(28,408)	(16,493)	(13,672)	2,821
973	948	(25)		122	8,094	7,869	(225)	1,076	5,113	4,813	(300)
Clinical Services											
374	347	(27)			3,367	3,121	(245)	4,162	4,489	4,162	(327)
5,895	5,779	(115)			53,906	53,029	(877)	69,057	72,420	73,269	849
6,269	6,126	(143)			57,273	56,150	(1,122)	73,219	76,909	77,431	522
(5,473)	(5,284)	190		803	(49,434)	(47,935)	1,499	(59,448)	(65,839)	(65,596)	243
0	(64)	(64)		0	0	(1,238)	(1,238)	(1,671)	(3,751)	(2,234)	1,517
(5,473)	(5,348)	126		803	(49,434)	(49,173)	261	(61,119)	(69,590)	(67,830)	1,760
795	778	(17)		803	7,838	6,977	(861)	12,101	7,319	9,601	2,282
Organ Donation & Transplantation											
6,665	7,511	845			59,987	63,268	3,282	81,504	79,983	84,539	4,556
170	170	0			1,531	1,531	0	0	2,041	2,041	0
284	279	(5)			2,553	2,597	44	1,921	3,404	3,640	236
7,119	7,960	841			64,071	67,397	3,326	83,425	85,428	90,220	4,792
(5,756)	(6,075)	(318)		490	(53,661)	(52,943)	718	(63,376)	(71,926)	(70,713)	1,213
(362)	(612)	(250)		30	(3,261)	(5,202)	(1,941)	(10,500)	(4,488)	(8,102)	(3,614)
(6,119)	(6,687)	(568)		520	(56,922)	(58,145)	(1,223)	(73,876)	(76,414)	(78,815)	(2,401)
1,000	1,273	273		520	7,149	9,252	2,103	9,550	9,015	11,406	2,391
Tissues and Eye Services											
1,432	1,357	(75)			12,954	12,227	(727)	15,062	17,937	16,236	(1,701)
46	42	(5)			416	375	(41)	0	554	500	(54)
1,478	1,398	(80)			13,370	12,602	(768)	15,062	18,491	16,737	(1,755)
(1,075)	(1,079)	(4)		153	(9,795)	(9,755)	40	(12,468)	(13,043)	(12,975)	68
(1,075)	(1,079)	(4)		153	(9,795)	(9,755)	40	(12,468)	(13,043)	(12,975)	68
403	319	(84)		153	3,575	2,847	(727)	2,595	5,449	3,762	(1,687)
NHSBT Summary											
44,129	44,587	459			397,424	398,667	1,243	514,063	531,293	530,897	(396)
(43,463)	(45,187)	(1,724)		5,282	(396,299)	(391,932)	4,367	(522,826)	(539,426)	(538,969)	457
666	(600)	(1,266)		5,282	1,125	6,735	5,610	(8,764)	(8,133)	(8,072)	61

Blood and Group - December 2022

Blood Supply (£)m	WTE		Year to Date Actual			Full Year Forecast		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Blood and Component Income			230.2	229.7	(0.4)	306.8	306.4	(0.4)
Other Blood Supply Income			2.6	3.0	0.4	3.5	4.0	0.5
Total Income			232.8	232.8	(0.0)	310.3	310.4	0.1
Cost of Sales - Blood Component Stock Movement			0.8	1.1	0.3	0.0	1.1	1.1
Blood Donation	1,420	1,485	(57.0)	(59.9)	(2.9)	(75.3)	(80.0)	(4.7)
Manufacturing, Testing & Issue	732	723	(50.0)	(51.6)	(1.6)	(66.4)	(68.9)	(2.5)
Logistics	310	319	(16.6)	(18.0)	(1.4)	(22.2)	(24.0)	(1.9)
Total Expenditure	2,462	2,527	(122.9)	(128.4)	(5.6)	(164.0)	(171.8)	(7.9)



Blood Supply Operating Surplus/(Deficit)	2,462	2,527	109.9	104.3	(5.6)	146.4	138.6	(7.8)
---	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------

Group Services (incl. Change Programme)	1,222	1,171	(135.4)	(124.5)	10.9	(181.4)	(176.3)	5.2
--	--------------	--------------	----------------	----------------	-------------	----------------	----------------	------------

Group Services detail on page 6

Blood and Group Surplus/(Deficit)	3,684	3,698	(25.5)	(20.2)	5.3	(35.0)	(37.7)	(2.6)
--	--------------	--------------	---------------	---------------	------------	---------------	---------------	--------------

Year to date, Blood Supply are reporting £5.6m adverse cost variance against plan driven by a combination of factors;

- Impact of the higher than budget pay inflation
- Higher use of overtime and temporary staff in Collections and Manufacturing
- Inflationary fuel pressures and increased usage of couriers

The full year effect of these pressures are reflected in the forecast outturn. Combining these with the planned productivity savings in collections that will no longer be delivered and the latest resourcing plans to increase headcount in response to the ongoing stock challenge, Blood Supply are expected to finish the year significantly higher than budget.

Group Services - December 2022

Group Services (£)m	WTE		Year to Date Actual			Full Year Forecast		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Programme Funding			9.3	8.4	(0.9)	12.4	11.2	(1.2)
Group Services Income			1.3	1.3	0.1	1.7	1.9	0.2
Medical			1.2	1.6	0.4	1.6	1.7	0.1
Research & Development			2.1	1.9	(0.2)	2.8	2.8	0.0
Total Income			13.9	13.2	(0.7)	18.5	17.6	(0.9)
Chief Executive and Board	4	3	(0.6)	(0.5)	0.1	(0.8)	(0.8)	(0.0)
Donor Experience	191	177	(18.2)	(18.2)	0.0	(23.9)	(25.8)	(1.9)
Quality	129	132	(6.4)	(6.2)	0.2	(8.6)	(8.4)	0.3
Estates & Facilities	80	77	(37.0)	(36.6)	0.4	(49.0)	(49.7)	(0.7)
Finance	111	99	(5.4)	(5.4)	0.0	(7.3)	(7.5)	(0.2)
Strategy and Transformation	14	10	(0.8)	(0.8)	(0.0)	(1.0)	(1.1)	(0.0)
People	153	152	(8.3)	(8.1)	0.2	(11.0)	(11.5)	(0.4)
Digital, Data and Technology Services	301	275	(32.4)	(29.0)	3.4	(44.3)	(40.7)	3.6
Research & Development	47	36	(4.8)	(4.5)	0.3	(6.3)	(6.2)	0.1
Medical	193	179	(13.4)	(13.3)	0.0	(18.0)	(17.4)	0.7
Miscellaneous and Capital Charges	0	0	(9.4)	(10.8)	(1.4)	(12.5)	(14.0)	(1.5)
Total Expenditure	1,222	1,141	(136.8)	(133.4)	3.4	(182.9)	(183.1)	(0.1)
Operating Surplus/(Deficit)	1,222	1,141	(122.9)	(120.2)	2.7	(164.4)	(165.5)	(1.1)
Change Programme	0	30	(12.6)	(4.4)	8.2	(17.0)	(10.8)	6.2
Group Services Surplus/(Deficit)	1,222	1,171	(135.4)	(124.5)	10.9	(181.4)	(176.3)	5.2

Year to date, Group Services (excluding the Change Programme) is reporting a £2.7m positive variance against plan. This predominantly reflects underspends reported in DDTs, driven by unfilled vacancies (26 under established) and the re-categorisation of BTM expenditure to capital.

The latest forecast implies that, this position will deteriorate, with increased pressures profiled throughout Q4. Including;

- super inflated estate utility costs (-£0.6m)
- Estate development works profiled in Q4 (-£0.5m)
- BAU direct marketing catch up and increased activity to support Blood stocks levels (-£1.9m)
- selling of Annual Leave (-£0.4m)

The latest transformation plan is currently sitting at c£10.8m, due to the re-categorisation of Blood Technology Modernisation and the reprofiling of Colindale Estates costs into 2023/24.

Clinical Services - December 2022 (operating contributions - pre ABC analysis)

(£)m	WTE		Year to Date Actual			Full Year Forecast		
	Budget	Actual	Budget	Actual	Variance	Budget	Fcst.	Variance
Red Cell Immunohematology (inc Reagents and IBGRL)								
Income			16.9	16.9	0.0	22.6	22.5	(0.1)
Expenditure			(12.9)	(12.4)	0.6	(17.2)	(16.6)	0.6
RCI - direct contribution	250	228	3.9	4.5	0.6	5.3	5.9	0.6
Histocompatibility & Immunogenetics								
Income			11.9	12.4	0.5	16.0	16.7	0.8
Expenditure			(11.8)	(11.6)	0.2	(15.7)	(16.0)	(0.3)
H&I - direct contribution	177	170	0.1	0.7	0.6	0.3	0.7	0.4
Pathology Total - WTE / direct contribution								
	427	398	4.1	5.3	1.2	5.6	6.6	1.0
Therapeutic Apheresis Services								
Income			8.8	10.3	1.4	11.8	13.5	1.6
Expenditure			(7.0)	(7.8)	(0.8)	(9.4)	(10.4)	(1.0)
TAS - direct contribution	99	100	1.8	2.5	0.7	2.5	3.1	0.6
Cord Blood Bank and British Bone Marrow Registry								
Income - prices			5.8	5.0	(0.8)	7.6	7.0	(0.6)
Expenditure			(2.6)	(2.4)	0.2	(3.4)	(3.1)	0.3
SCGT - direct contribution	46	45	3.2	2.6	(0.6)	4.2	3.9	(0.3)
CBC								
Income			3.5	1.5	(2.0)	4.4	3.3	(1.1)
Expenditure			(2.7)	(3.2)	(0.5)	(3.6)	(3.8)	(0.2)
CBC - direct contribution	37	34	0.8	(1.7)	(2.5)	0.8	(0.5)	(1.3)
Cellular & Molecular Therapies (exc CBC)								
Income			10.3	10.1	(0.2)	14.4	14.0	(0.5)
Expenditure			(7.8)	(7.0)	0.8	(10.4)	(9.8)	0.7
CMT I&E	108	101	2.5	3.0	0.6	4.0	4.2	0.2
CAGT Total - WTE / direct contribution								
	290	280	8.3	6.4	(1.8)	11.4	10.7	(0.7)
Transfusion excl. R&D / Medical (within Group Services)								
	39	48	(0.9)	(0.6)	0.3	(1.2)	(1.4)	(0.2)
DTS Management								
	46	35	(3.6)	(2.9)	0.7	(4.8)	(4.1)	0.7
TOTAL - WTE / Operating Surplus/(Deficit)								
	803	760	7.8	8.2	0.4	11.1	11.8	0.8
Change Programme								
	0	6	0.0	(1.2)	(1.2)	(3.8)	(2.2)	1.5
TOTAL - WTE / Clinical Services Surplus/(Deficit)								
	803	766	7.8	7.0	(0.9)	7.3	9.6	2.3

At the end of December, Clinical Services (pre ABC analysis) is reporting £0.4m ahead of plan (excluding change programme). This is predominately driven by higher income across H&I and TAS combined with vacancies reported within the Division.

Summary by Business Unit:

RCI; driven primarily by unfilled vacancies.


H&I; contribution above plan driven by strong Solid Organ and Diseased Association Investigation activity year to date. The latest forecast implies that the higher run rate will continue over the remainder of the year.

TAS; year to date, TAS are reporting favourable activity variances in Photopheresis and Red Cell exchange, resulting in a positive position against plan. The forecast expects activity to continue to be ahead of plan.

CBC; adverse position against plan due to slippages in high value contracts. The income position looks to improve as the forecast expects a further £1.3m to be received in March.

Cord Blood Bank and Bone Marrow Registry; Both cord blood issues and BBMR harvest behind plan. The latest forecast does not expect Cord activity to achieve plan generating a worsening year end position. However the BBMR harvest income is expect to improve with an higher ratio of international to UK issues.

CMT; reduced income relating to ACT projects being delayed into 2023/24, however, this is more than offset by reduced non pay and vacancies through CMT.



Note: Excludes Medical and R&D funding.

Organ Donation and Transplant – December 2022

ODT I&E (£)m	WTE		Year to Date Actual			Full Year Forecast		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Programme Funding			52.0	54.4	2.3	69.4	72.5	3.1
Other UK Health Authorities Funding			9.5	10.4	1.0	12.6	14.1	1.5
NHSE Funding			2.6	2.6	0.0	3.4	3.6	0.2
Total Funding			64.1	67.4	3.3	85.4	90.2	4.8
Operating Expenditure	490	468	(53.7)	(52.9)	0.7	(71.9)	(70.7)	1.2
Transformation	30	25	(3.3)	(5.2)	(1.9)	(4.5)	(8.1)	(3.6)
Total Expenditure	520	493	(56.9)	(58.1)	(1.2)	(76.4)	(78.8)	(2.4)
ODT Surplus/(Deficit)	520	493	7.1	9.3	2.1	9.0	11.4	2.4
Direct contribution to Group Services						(10.8)	(10.8)	0.0
ODT Deficit (funded by cash)						(1.8)	0.6	2.3

The ODT budget envelope for 2022/23 is based on flat funding from DHSC. The resulting deficit at operational level (£1.8m).

Due to lower activity, ODT are now forecasting a small underlying surplus of £0.6m, driven by reduced activity related expenditure and increased funding contribution from Wales and Scotland.

DHSC have also confirmed that additional funding (+£3.6m) can be drawn down to match the in year costs for DCD Hearts, which has been reflected in the Q3 forecast.

Going into 2023/24 the underlying deficit is set to increase further, reflecting an incremental increase to activity (per the ODT strategy) and inflation pressures vs flat funding over the SR21 period. This funding gap will need to be addressed well in advance of 2023/24.

Tissue and Eye Services – December 2022

Year to date, TES are reporting an income shortfall against plan, primarily driven by lower Cornea issues. The forecast implies that this lower run rate will continue throughout the remainder of the year.

TES I&E (£)m	WTE		Year to Date Actual			Full Year Forecast		
	Bud.	Per Act.	Bud.	Act.	Var.	Budget	Fcst.	Variance
Income						13.4	12.6	(0.8)
Cost of Sales						(0.4)	(0.3)	0.1
Expenditure			153	146		(9.4)	(9.5)	(0.1)
Surplus/(Deficit)			153	146		3.6	2.8	(0.7)
						5.4	3.8	(1.7)

Plasma for Medicine - December 2022

Plasma for Medicine (£)m	WTE		Year to Date			Full Year Forecast		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Programme Funding			10.6	10.9	0.3	14.1	8.6	(5.5)
Plasma for Diagnostics Income			5.5	5.6	0.2	7.5	9.8	2.3
Expenditure	122	145	(7.9)	(8.7)	(0.7)	(16.5)	(13.7)	2.8
Programme Surplus/(Deficit)	122	145	8.1	7.9	(0.2)	5.1	4.8	(0.3)

For 2022/23, the Plasma plan is fully funded by a combination of cash reserves and Plasma for Diagnostics income.

The 2022/23 budget envelope estimated a group service contribution of £5.1m, however, ABC analysis/allocation has resulted in an overhead allocation of £4.8m. The balance (£0.3m) will be treated as increased funding carried forward into 2023/24.

Cash Flow – as at December 2022

	Actual Apr-22 £k	Actual May-22 £k	Actual Jun-22 £k	Actual Jul-22 £k	Actual Aug-22 £k	Actual Sep-22 £k	Actual Oct-22 £k	Actual Nov-22 £k	Actual Dec-22 £k	Forecast Jan-23 £k	Forecast Feb-23 £k	Forecast Mar-23 £k	Total £k
Opening bank balance	64,676	72,432	75,293	69,908	89,346	85,291	85,549	78,791	69,852	70,006	73,272	58,201	64,676
Receipts													
Debtors & Other Receipts	33,604	39,970	34,671	34,788	36,027	37,197	40,547	37,162	34,382	40,178	40,259	42,831	451,616
Revenue Cash Limit	0	0	0	23,833	5,958	5,958	5,958	5,958	5,958	5,958	5,958	5,958	71,500
Revenue Cash Limit - Pensions Uplift	0	0	0	3,680	920	935	935	935	935	933	929	998	11,200
Revenue Cash Limit - DCD Hearts	0	0	0	0	0	0	0	0	0	0	3,300	300	3,600
Capital Cash Limit	0	0	0	3,000	0	0	0	0	0	4,000	4,000	4,000	15,000
Total Receipts	33,604	39,970	34,671	65,301	42,905	44,090	47,440	44,055	41,276	51,070	54,447	54,088	552,916
Payments													
Staff Expenses	6,743	21,016	21,338	21,413	20,986	23,460	24,359	22,692	22,247	25,838	24,548	35,286	269,926
Other Revenue Payments	18,359	15,949	18,378	24,022	25,932	19,396	18,999	30,232	17,557	21,009	21,664	32,884	264,382
Capital Charges Less DH Credit Due	0	0	0	0	0	0	10,437	0	0	0	10,437	0	20,874
Capital Payments	746	144	340	427	42	975	403	70	1,317	1,200	2,000	7,335	15,000
Total Payments	25,848	37,109	40,055	45,863	46,961	43,832	54,198	52,995	41,121	48,047	58,649	75,505	570,183
Closing bank balance	72,432	75,293	69,908	89,346	85,291	85,549	78,791	69,852	70,006	73,029	68,827	47,410	47,410

Debtor Days (Target is 22 days)	17	14	13	18	17	19	17	14	19
YTD BPPC By Value % (Target is 95%)	86.9%	91.1%	93.5%	94.6%	93.4%	93.7%	93.8%	93.6%	93.6%
YTD BPPC By Number % (Target is 95%)	92.8%	93.1%	93.3%	93.5%	93.4%	93.3%	93.2%	93.0%	93.1%

Overdue Debtors NBS/ODT £000's	1-30 Days overdue £000's	31-60 Days overdue £000's	61-90 Days overdue £000's	>90 Days overdue £000's	Total Overdue £000's
Total Overdue Debtors	5,811	2,036	516	612	8,975

Top 5 > 90 days Overdue Debtors £000's	Nov-22		Dec-22	
	>90 Days overdue £000's	Total Overdue £000's	>90 Days overdue £000's	Total Overdue £000's
IMPERIAL COLLEGE HEALTHCARE NHS TRUST	72	116	79	825
BARTS HEALTH NHS TRUST	78	196	76	212
KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST	54	131	74	407
HULL UNIVERSITY TEACHING HOSPITALS NHS TRUST			42	196
GUY'S AND ST. THOMAS' NHS FOUNDATION TRUST	129	827	41	326
UNIVERSITY OF BRISTOL	68	68		
Total 5 Overdue Debtors	402	1,338	312	1,967
Other Debtors	271	5,807	300	7,008
Total Overdue Debtors	673	7,144	612	8,975

Notional Split	£m
Blood	13.7
Clinical Services	7.9
ODT	11.3
Plasma	14.6
NHSBT Total	47.5

>90 DAYS OVERDUE	Profile by Month													
	Actual Apr-22 £000s	Actual May-22 £000s	Actual Jun-22 £000s	Actual Jul-22 £000s	Actual Aug-22 £000s	Actual Sep-22 £000s	Actual Oct-22 £000s	Actual Nov-22 £000s	Actual Dec-22 £000s	Actual Jan-23 £000s	Actual Feb-23 £000s	Actual Mar-23 £000s		
	Target Range Between £0.5m and £1.0m													
Ledger Balance at month end	330	413	686	680	536	922	709	673	612					

Contribution Statement– as at December 2022

Post allocation of costs via the ABC model

Year to date Actual £m	Blood & Components inc. R&D	Plasma	Pathology		CAGT				TES	ODT	NHSBT
			RCI	H&I	CMT	CBC	SCDT	TAS			
Income/Funding											
Prices	232.4	0.0	16.0	10.8	9.9	0.0	3.1	9.9	12.2	0.0	294.4
Central Funding from DHAs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.2	10.2
Grant in Aid (DHSC Funding)	6.9	11.0	0.2	1.4	0.1	0.0	1.9	0.1	0.5	55.1	77.2
Other	5.3	5.6	0.8	0.3	0.2	1.5	0.0	0.4	0.0	2.9	17.0
Total Income/Funding	244.6	16.6	17.0	12.5	10.2	1.5	5.0	10.4	12.7	68.1	398.7
Expenditure											
Variable Costs	(28.0)	(0.5)	(1.4)	(3.0)	(1.6)	(1.2)	(0.2)	(3.1)	(2.1)	(2.6)	(43.6)
Variable Contribution	216.6	16.1	15.6	9.5	8.6	0.4	4.9	7.3	10.7	65.5	355.1
Direct Costs	(98.8)	(5.7)	(10.0)	(6.1)	(5.4)	(2.1)	(2.8)	(4.5)	(8.1)	(52.6)	(196.1)
Direct Contribution	117.8	10.5	5.6	3.4	3.2	(1.7)	2.0	2.7	2.6	12.9	158.9
Direct Support Costs	(82.4)	(2.3)	(4.1)	(1.6)	(3.6)	(0.7)	(1.3)	(1.0)	(2.6)	(8.1)	(107.8)
Total Allocated Costs	(209.2)	(8.5)	(15.5)	(10.6)	(10.6)	(4.0)	(4.4)	(8.6)	(12.8)	(63.3)	(347.6)
Total Unallocated Costs	(18.4)	(0.9)	(1.4)	(0.9)	(0.9)	(0.3)	(0.4)	(0.8)	(1.1)	(5.9)	(31.1)
Operating Net Surplus / (Deficit)	16.9	7.2	0.2	0.9	(1.3)	(2.8)	0.3	1.0	(1.2)	(1.1)	20.0
Transformation	(4.4)	(2.5)	(0.4)	(0.2)	(0.2)	(0.1)	(0.1)	(0.2)	-	(5.2)	(13.3)
Net Surplus / (Deficit) Inc Transformation	12.5	4.7	(0.2)	0.7	(1.5)	(2.9)	0.1	0.7	(1.2)	(6.3)	6.7
Budget	8.3	4.7	(0.6)	0.2	(2.3)	(0.4)	0.8	0.4	(0.8)	(9.1)	1.1
Variance	4.3	0.0	0.4	0.5	0.8	(2.4)	(0.7)	0.3	(0.4)	2.8	5.6
RAG	G	G	G	G	G	R	R	G	R	G	G

Notes;

Blood at "Green" but results from the favourable group services and change programme position.

CBC – adverse position against plan due to slippages in high value contracts

Stem Cell and Donation – reporting red as BBMR income and CBB issues are behind plan.

TES – reporting red reflecting lower cornea activity.

i) This report reflects the final version of the ABC model for 2022/23, and includes adjustments arising from a review of cost allocation data since the original indicative draft.

ii) Work is ongoing to develop the model for 2023/24 planning and reporting, which will include further updates.